Nerelimomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | TNF alpha |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Nerelimomab is a mouse monoclonal antibody acting as a TNF inhibitor.[1][2]
References
[edit]- ^ "WHO Drug Information" (PDF). Archived from the original (PDF) on 2012-02-19. Retrieved 2009-09-24.
- ^ Huang L, Du B, Cui X, Zhao H, Feng Y, Xu Z, et al. (December 2024). "Nerelimomab Alleviates Capsaicin-Induced Acute Lung Injury by Inhibiting TNF Signaling and Apoptosis". Pharmaceuticals. 17 (12). Basel, Switzerland: 1694. doi:10.3390/ph17121694. PMC 11676931. PMID 39770536.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |